文献速递白血病

青少年及年轻成人AML:儿科与成人方案疗效对比

Outcomes of adolescents and young adults with AML treated on pediatric vs adult protocols.
PubMed 文献 · Blood Adv · 2026-01-01

单中心回顾性研究分析81例14-29岁新诊断AML患者,比较儿科与成人方案诱导治疗。两组复合完全缓解率(79% vs 78%)及MRD阴性率(63% vs 55%)相似,但成人方案组5年总生存更优(77.9% vs 56.7%),无复发生存几乎相同。多变量分析显示ELN 2022风险分层保留独立预后意义,治疗方案则否。

要点

  • 儿科与成人方案在AYA-AML中达到相似的缓解深度与MRD阴性率。
  • 成人方案组5年总生存优于儿科方案组,尤其在ELN中高危亚组。
  • ELN 2022风险分层是独立预后因素,治疗方案非独立因素。

核心结论

  • 儿科风格与成人AML方案在AYA患者中实现相当的缓解深度。
  • 成人方案观察到的生存优势挑战了进一步细胞毒强化可改善结局的假设。

研究设计与样本

  • 单中心回顾性研究,纳入2010至2025年Memorial Sloan Kettering Cancer Center的81例14-29岁新诊断AML患者。
  • 按治疗服务、ELN 2022风险分层及诱导方案分组。

主要发现

  • 成人组与儿科组复合完全缓解率分别为79%与78%。
  • 应答者中多色流式细胞术检测MRD阴性率分别为63%与55%。
  • 5年总生存:全队列成人组77.9% vs 儿科组56.7%;ELN 2022中高危亚组成人组62.7% vs 儿科组47.9%。
  • 无复发生存两组几乎相同。
  • 多变量分析中ELN 2022风险保留独立预后意义,治疗方案无独立意义。

关键数值与推荐

  • 儿科方案:2周期以阿糖胞苷、柔红霉素和依托泊苷为基础的诱导治疗。
  • 成人方案:1周期阿糖胞苷联合柔红霉素(7+3)诱导,其中3例需7+3再诱导,随后进行风险适应性巩固治疗包括异基因造血干细胞移植。

临床怎么用

  • AYA-AML患者选择成人方案可能获得生存优势,无需常规采用儿科强化方案。
  • 应依据ELN 2022风险分层指导治疗决策与巩固策略。

局限性

  • 单中心回顾性设计,样本量81例,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adolescents and young adults (AYA) with acute myeloid leukemia (AML) represent a biologically and clinically distinct population managed across pediatric and adult oncology services, with no established optimal treatment paradigm. In this single-center retrospective study, we analyzed 81 AYA patients aged 14 to 29 years with newly diagnosed AML treated at Memorial Sloan Kettering Cancer Center between 2010 and 2025. Patients were stratified by treating service, European LeukemiaNet (ELN) 2022 risk category, and induction regimen. Pediatric patients received 2 cycles of cytarabine, daunorubicin, and etoposide-based induction, whereas adult patients received 1 cycle of cytarabine plus daunorubicin (7+3) induction, 3 of whom required 7+3 reinduction, followed by risk-adapted consolidation including allogeneic hematopoietic stem cell transplantation. Composite complete response rates were similar between adult and pediatric cohorts (79% vs 78%), as were rates of minimal residual disease negativity by multicolor flow cytometry among responders (63% vs 55%). Despite comparable depth of response, 5-year overall survival favored adult-service patients in both the full cohort (77.9% vs 56.7%) and the ELN 2022 intermediate-adverse risk subgroup (62.7% vs 47.9%), whereas relapse-free survival was nearly identical. On multivariable analysis, ELN 2022 risk retained independent prognostic significance, whereas treatment protocol did not. These findings demonstrate that pediatric-style and adult AML regimens achieve comparable remission depth in AYA patients. The survival advantage observed with adult protocols challenges the assumption that further cytotoxic intensification improves outcomes in this population.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Krayem B, Biswas J, Derkach A, et al. Outcomes of adolescents and young adults with AML treated on pediatric vs adult protocols. Blood Adv. 2026. PMID: 42314040. doi:10.1182/bloodadvances.2026020372

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。